Related Experiment Video

Updated: May 5, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

Low ADAMTS-13 in plavix induced thrombotic thrombocytopenic purpura

Long Bao Cao1, Christopher Jones, Assad Movahed

  • 1Long Bao Cao, Christopher Jones, Assad Movahed, Department of Cardiovascular Sciences, Brody School of Medicine, East Carolina University, Greenville, NC 27834, United States.

World Journal of Clinical Cases
|December 5, 2013
PubMed

Insights

Thrombotic thrombocytopenia purpura (TTP) is a rare condition linked to antiplatelet drugs. This case highlights clopidogrel-induced TTP presenting with severe stroke, renal failure, and myocardial infarction.

Area of Science:

  • Hematology
  • Cardiology
  • Neurology

Background:

  • Thrombotic thrombocytopenia purpura (TTP) is a critical condition characterized by microvascular thrombosis.
  • Drug-induced TTP, particularly associated with antiplatelet agents like ticlopidine and clopidogrel, is linked to reduced ADAMTS-13 activity.

Observation:

  • A patient presented with acute stroke, renal failure, and non-ST elevation myocardial infarction.
  • This clinical presentation was attributed to clopidogrel-associated TTP.

Findings:

  • The case suggests a potential association between clopidogrel use and the development of TTP.
  • The patient experienced severe thrombotic events, including stroke, myocardial infarction, and renal failure.

Implications:

  • This case underscores the importance of considering drug-induced TTP in patients presenting with multi-organ thrombotic events.
  • Awareness of clopidogrel's potential role in TTP is crucial for timely diagnosis and management.
  • Further investigation into the mechanisms of clopidogrel-induced TTP and its association with ADAMTS-13 activity is warranted.
Keywords:
Antiplatelet therapyPlavixThrombotic thrombocytopenic purpura

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

174
In Vitro Thrombosis Test for Ventricular Assist Devices09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.3K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K